Literature DB >> 24213571

High mobility group box 1 promotes tumor cell migration through epigenetic silencing of semaphorin 3A.

M Nehil1, J Paquette2, T Tokuyasu2, F McCormick2.   

Abstract

High mobility group box 1 (HMGB1) is a 25-kDa chromatin-associated protein that aids in transcription and DNA repair by directly binding to DNA and altering its conformation. Additionally, HMGB1 can act as an extracellular ligand. When released from dying or stressed cells, HMGB1 binds to the RAGE receptor and activates the p42/44 MAP kinase (MAPK) cascade. HMGB1 is overexpressed in many types of cancer and frequently associated with tumor stage and metastasis. This has predominantly been attributed to an autocrine function that drives MAPK pathway activity. However, by using tumor cells with activating MAPK pathway mutations, we have identified a role for HMGB1 in promoting metastasis and tumor growth that is independent of this pathway. In the absence of HMGB1, these tumor cells show defective in vitro migration as well as reduced metastasis and tumor growth in vivo despite high p42/44 phosphorylation. We found that semaphorin 3A (SEMA3A), previously shown to act as a suppressor of angiogenesis and migration, was highly increased during expression in the absence of HMGB1. SEMA3A/HMGB1 double knockdown rescued the migration defect in HMGB1 single knockdown cells. HMGB1 bound at the semaphorin 3A genomic locus, promoted hetrochromatin formation, and decreased occupancy of acetylated histones. Based on human tumor gene expression databases, HMGB1 was significantly inversely correlated with SEMA3A, suggesting that this mechanism may be more widely relevant in different cancer types.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24213571     DOI: 10.1038/onc.2013.459

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  9 in total

Review 1.  The role of the semaphorins in cancer.

Authors:  Gera Neufeld; Yelena Mumblat; Tatyana Smolkin; Shira Toledano; Inbal Nir-Zvi; Keren Ziv; Ofra Kessler
Journal:  Cell Adh Migr       Date:  2016-08-17       Impact factor: 3.405

Review 2.  Trained Immunity as a Trigger for Atherosclerotic Cardiovascular Disease-A Literature Review.

Authors:  Natalia Anna Zieleniewska; Małgorzata Kazberuk; Małgorzata Chlabicz; Andrzej Eljaszewicz; Karol Kamiński
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

3.  Hepatitis B virus X protein counteracts high mobility group box 1 protein-mediated epigenetic silencing of covalently closed circular DNA.

Authors:  Elena S Kim; Jun Zhou; Hu Zhang; Alexander Marchetti; Maarten van de Klundert; Dawei Cai; Xiaoyang Yu; Bidisha Mitra; Yuanjie Liu; Mu Wang; Ulrike Protzer; Haitao Guo
Journal:  PLoS Pathog       Date:  2022-06-09       Impact factor: 7.464

4.  Identification of epigenetic modifications that contribute to pathogenesis in therapy-related AML: Effective integration of genome-wide histone modification with transcriptional profiles.

Authors:  Xinan Holly Yang; Bin Wang; John M Cunningham
Journal:  BMC Med Genomics       Date:  2015-05-29       Impact factor: 3.063

5.  Secreted HMGB1 from Wnt activated intestinal cells is required to maintain a crypt progenitor phenotype.

Authors:  Karen R Reed; Fei Song; Maddy A Young; Nurudeen Hassan; Daniel J Antoine; Nesibe-Princess B Gemici; Alan R Clarke; John R Jenkins
Journal:  Oncotarget       Date:  2016-08-09

Review 6.  Class-3 Semaphorins and Their Receptors: Potent Multifunctional Modulators of Tumor Progression.

Authors:  Shira Toledano; Inbal Nir-Zvi; Rotem Engelman; Ofra Kessler; Gera Neufeld
Journal:  Int J Mol Sci       Date:  2019-01-28       Impact factor: 5.923

7.  Role of high-mobility group box 1 in methamphetamine-induced activation and migration of astrocytes.

Authors:  Yuan Zhang; Tiebing Zhu; Xiaotian Zhang; Jie Chao; Gang Hu; Honghong Yao
Journal:  J Neuroinflammation       Date:  2015-09-04       Impact factor: 8.322

8.  Hypoxia-conditioned media allows species-specific attraction of bone marrow stromal cells without need for recombinant proteins.

Authors:  Anastasia Gabrielyan; Sven Knaak; Michael Gelinsky; Stefan Arnhold; Angela Rösen-Wolff
Journal:  BMC Vet Res       Date:  2014-03-04       Impact factor: 2.741

Review 9.  The emerging role of class-3 semaphorins and their neuropilin receptors in oncology.

Authors:  Patrick Nasarre; Robert M Gemmill; Harry A Drabkin
Journal:  Onco Targets Ther       Date:  2014-09-24       Impact factor: 4.147

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.